Stephanie Gilibert, MD
Nephrology · Honolulu, HINPI 1972540789
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,427 of the $2,709 with a category attached, or 89.6%. 19 manufacturers reported payments, led by AstraZeneca at 25.6% of the total. Reporting peaked in 2019 at $911 and has fallen 74.3% since, to $235 in 2025.
Across 85 payments — averaging $31.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$693
- Amgen$354
- Bayer$279
- Ardelyx, Inc.$195
- Eurofins Viracor, LLC$184
- Aurinia Pharma U.S., Inc.$163
- plus $841 from 13 others
What the payments were for
- Food & beverage$2,42790%
- Education$28210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 21 | $693 |
| Amgen(2 entities) | 13 | $354 |
| Bayer | 12 | $279 |
| Ardelyx, Inc. | 9 | $195 |
| Eurofins Viracor, LLC | 1 | $184 |
| Aurinia Pharma U.S., Inc. | 6 | $163 |
| Bard Peripheral Vascular, Inc. | 1 | $134 |
| Veloxis Pharmaceuticals, Inc. | 5 | $131 |
| Vifor Pharma, Inc. | 1 | $118 |
| Mallinckrodt Hospital Products Inc. | 2 | $114 |
| Mallinckrodt Enterprises LLC | 1 | $72 |
| GSK | 2 | $70 |
| E.r. Squibb & Sons, L.L.C. | 3 | $43 |
| Otsuka America Pharmaceutical, Inc. | 2 | $37 |
| Boehringer Ingelheim | 2 | $31 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Travere Therapeutics, Inc. | 1 | $24 |
| Calliditas Therapeutics US Inc. | 1 | $24 |
| Fresenius USA Marketing, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,709 in reported general payments places this provider in the 60th percentile of 57 nephrology providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KerendiaFinerenone | 82 | $122,112 |
| FarxigaDapagliflozin Propanediol | 95 | $118,596 |
| XphozahTenapanor Hcl | 32 | $112,758 |
| BenlystaBelimumab | 12 | $57,330 |
| JardianceEmpagliflozin | 37 | $56,574 |
| AranespDarbepoetin Alfa In Polysorbat | 15 | $25,806 |
| LokelmaSodium Zirconium Cyclosilicate | 23 | $23,118 |
| ProcritEpoetin Alfa | 11 | $20,212 |
| JanuviaSitagliptin Phosphate | 11 | $18,647 |
| Sevelamer Carbonate | 40 | $10,074 |
| Losartan Potassium | 195 | $3,166 |
| Calcitriol | 119 | $2,943 |
| Tamsulosin Hcl | 75 | $2,201 |
| Metoprolol Succinate | 100 | $2,091 |
| Calcium Acetate | 25 | $2,082 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $693 | $141,714118 claims |
| BayerKerendia | $279 | $122,11282 claims |
| GSKBenlysta | $70 | $57,33012 claims |
| Boehringer IngelheimJardiance | $31 | $56,57437 claims |
| AmgenAranesp | $354 | $25,80615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 57 nephrology providers in Hawaii.
Other nephrology in Honolulu
- Kunal ParekhHonolulu$172K
- Christie IzutsuHonolulu$50K
- Jared SugiharaHonolulu$39K
- Eugene WongHonolulu$37K
- Shiuh ChengHonolulu$21K
- Leilani Ka'aneheHonolulu$10K
- Antonette Veronica HernandezHonolulu$9K
- Rick HayashiHonolulu$5K
- David NaaiHonolulu$5K
- Arie Olivo GanzHonolulu$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.